In the past week, RLMD stock has gone down by -7.61%, with a monthly decline of -22.13% and a quarterly plunge of -89.95%. The volatility ratio for the week is 11.52%, and the volatility levels for the last 30 days are 11.82% for Relmada Therapeutics Inc The simple moving average for the past 20 days is -9.85% for RLMD’s stock, with a -87.79% simple moving average for the past 200 days.
Is It Worth Investing in Relmada Therapeutics Inc (NASDAQ: RLMD) Right Now?
The 36-month beta value for RLMD is at 0.61. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for RLMD is 25.28M, and currently, shorts hold a 3.31% of that float. The average trading volume for RLMD on February 21, 2025 was 1.70M shares.
RLMD) stock’s latest price update
The stock price of Relmada Therapeutics Inc (NASDAQ: RLMD) has plunged by -3.31 when compared to previous closing price of 0.31, but the company has seen a -7.61% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-06 that Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB
Analysts’ Opinion of RLMD
Many brokerage firms have already submitted their reports for RLMD stocks, with Mizuho repeating the rating for RLMD by listing it as a “Neutral.” The predicted price for RLMD in the upcoming period, according to Mizuho is $1 based on the research report published on December 05, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see RLMD reach a price target of $13, previously predicting the price at $3.50. The rating they have provided for RLMD stocks is “Buy” according to the report published on September 17th, 2024.
Goldman gave a rating of “Sell” to RLMD, setting the target price at $2 in the report published on June 05th of the previous year.
RLMD Trading at -19.77% from the 50-Day Moving Average
After a stumble in the market that brought RLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.80% of loss for the given period.
Volatility was left at 11.82%, however, over the last 30 days, the volatility rate increased by 11.52%, as shares sank -19.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.51% lower at present.
During the last 5 trading sessions, RLMD fell by -7.43%, which changed the moving average for the period of 200-days by -91.73% in comparison to the 20-day moving average, which settled at $0.3368. In addition, Relmada Therapeutics Inc saw -41.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLMD starting from TRAVERSA SERGIO, who purchase 51,407 shares at the price of $2.99 back on Sep 11 ’24. After this action, TRAVERSA SERGIO now owns 384,024 shares of Relmada Therapeutics Inc, valued at $153,707 using the latest closing price.
TRAVERSA SERGIO, the Chief Executive Officer of Relmada Therapeutics Inc, purchase 55,579 shares at $2.71 during a trade that took place back on Sep 09 ’24, which means that TRAVERSA SERGIO is holding 299,603 shares at $150,619 based on the most recent closing price.
Stock Fundamentals for RLMD
The total capital return value is set at -1.92. Equity return is now at value -116.60, with -104.91 for asset returns.
Currently, EBITDA for the company is 4.91 million with net debt to EBITDA at 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.89.
Conclusion
In conclusion, Relmada Therapeutics Inc (RLMD) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
